abstract this disclosure relates to the use of anti-a-synuclein antibody to diagnose an elevated level of a-synuclein in the brain. specifically, the disclosure relates to the method of assessing the levels of a-synuclein in a blood plasma or csf following administration to the test subject of an anti-synuclein antibody or antigen-binding fragment thereof, which can bind a-synuclein with sufficient activity to alter the net efflux of a-synuclein from brain to blood, or from brain to csf. Translation of the Summary Patent Summary: "Use of an anti-alpha synuclein antibody to diagnose a high level of alpha synuclein in the brain". This disclosure relates to the use of the anti-α-synuclein antibody to diagnose a high level of α-synuclein in the brain. specifically, the disclosure relates to the method of evaluating α-synuclein levels in blood plasma or lcr following administration to the test subject of an anti-α-synuclein antibody or antigen-binding fragment thereof which may bind α-synuclein with sufficient activity to alter the net efflux of α-synuclein from brain to blood, or from brain to lcr.abstract this disclosure relates to the use of anti-a-synuclein antibody to diagnose an elevated level of a-synuclein in the brain. specifically, the disclosure relates to the method of assessing the levels of a-synuclein in a blood plasma or csf following administration to the test subject of an anti-a-synuclein antibody or antigen-binding fragment thereof, which can bind a-synuclein with sufficient activity to alter the net efflux of a-synuclein from brain to blood, or from brain to csf. tradução do resumo resumo patente de invenção: "uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro". esta divulgação refere-se ao uso do anticorpo anti-a-sinucleína para diagnosticar um nível elevado de a-sinucleína no cérebro. especificamente, a divulgação refere-se ao método de avaliação dos níveis de a-sinucleína no plasma sanguíneo o
